ZURA Stock Forecast & Price Target

Zura Bio is supported by a differentiated pipeline led by tibulizumab, a first-in-class BAFF x IL-17A bispecific that could address multiple autoimmune settings where current therapies leave substantial unmet need. The company’s outlook is strengthened by a funded balance sheet, with $205.1MM in cash and a reported net loss of $26.3MM in 2Q26, while the next catalysts in HS and SSc remain on track and the new PMR program expands the addressable opportunity. In PMR, the combination of high prevalence, only one approved biologic, and prior clinical validation for IL-17 and B-cell targeting underpins an attractive risk/reward setup that could support multibillion-dollar sales potential.

Zura Bio is viewed negatively because its investment case remains highly dependent on tibulizumab, and any clinical or regulatory failure in target indications would materially weaken the company’s prospects. The lead programs may fail to demonstrate sufficient efficacy or could encounter safety signals that halt development, while commercial execution risk remains elevated if sales estimates are not achieved amid competition from current and future therapies. In addition, manufacturing or shipment disruptions could impede development and commercialization, reinforcing the view that the company faces meaningful scientific, regulatory, and operational uncertainty.